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ABSTRACT 
 
LINDA PAQUETTE:  The Effect of Using a Powered Toothbrush on MCP-1 and RANTES 
Levels in Patients with Gingivitis  
Under the direction of Heather L. Jared, Rebecca S. Wilder, and Silvana P. Barros 
 
 
 This pilot study investigated if a powered toothbrush significantly reduced the 
concentration of MCP-1 and RANTES over time in a gingivitis population, when compared 
to a manual toothbrush.  Twenty gingivitis patients, 18-65 years of age with pocket depths ≤ 
6mm and a minimum of 10% bleeding upon probing were enrolled.  Participants were seen 
for 5 study visits and gingival crevicular fluid samples were collected at baseline and 24 
weeks.  With the exception of race (p=0.01), no statistically significant differences were 
found between the groups at baseline in clinical measurements, GCF levels of MCP-1 and 
RANTES and demographics.  When comparing the treatment group to the control, no 
statistical differences were found between the GCF levels for MCP-1 and RANTES at 
baseline and 24 weeks post treatment (p=0.20 and p=0.19, respectively).  Additional large 
sample studies are needed to determine if these findings can be confirmed. 
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ABBREVIATIONS 
α   Alpha 
β  Beta 
ANCOVA Analysis of covariance 
BOP  Bleeding on probing 
CAL  Clinical attachment level 
CEJ  Cementoenamel junction 
CRF  Case report form 
GCF  Gingival crevicular fluid 
GI  Gingival index 
IL-1β  Interleukin 1β 
IL-6  Interleukin 6 
IL-12  Interleukin 12 
MCP-1 Monocyte chemoattractant protein-1 
mm  Millimeter   
PD  Probing depth 
PGE2  Prostaglandin E2 
RANTES Regulated on activation, normal T cells expressed and secreted 
SD  Standard deviation 
TNF-α  Tumor necrosis factor-α 
  
INTRODUCTION 
 Gingivitis is an inflammatory condition initiated by the accumulation of biofilm on 
tooth surfaces in persons with inadequate oral hygiene.  According to Albander, 
approximately 50% of the adults in the United States have gingivitis.1 Historically, the 
assessment of gingival disease has been made using the static clinical parameters such as 
dental indices, bleeding on probing and clinical attachment levels.  These tests rely on the 
physical changes in the periodontium but do not offer insight into the multifactorial nature of 
the host response.2 The host response to inflammation elicits a cascade of inflammatory 
mediators including cytokines.   
 Effective plaque control, through proper brushing and flossing, is a necessity to stop 
the inflammatory response and prevent further damage to the periodontal structures.  Since 
the toothbrush is the most widely used method of plaque control, a variety of innovative 
powered toothbrushes, including sonic and ultrasonic, have been studied to assess their 
effectiveness in bacterial plaque removal.3-5 This pilot study attempted to assess the effect a 
powered toothbrush utilizing a combination of sonic and ultrasound technology would have 
on the cytokines, MCP-1 and RANTES, in a gingivitis group.  
 MCP-1 (monocyte chemoattractant protein-1) and RANTES (regulated on activation, 
normal T cells expressed and secreted) are members of a sub group of cytokines called 
chemokines.  Chemokines are pro-inflammatory mediators that recruit a well-defined set of
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leukocytes.  MCP-1 expression is highly correlated with the degree of gingival inflammation 
present.6 RANTES is involved in T-lymphocyte recruitment that controls cell-mediated 
immune response. 
 The potential diagnostic value of cytokines gained impetus with the identification of 
the episodic nature of periodontal diseases in the 1970s.7 Cytokines have been investigated as 
predictors of risk for periodontal diseases.8-10 The assessment of cytokines in gingival 
crevicular fluid offers a method of detecting susceptible individuals and may also suggest 
future lines of therapy.11 “Gingival crevicular fluid is easily obtainable and can be sampled 
repeatedly in a painless, non-invasive manner from periodontal sites of interest.”10   
 Even though cytokines have been investigated as markers for periodontal disease, 
there is a lack of literature on cytokines in healthy gingival tissue or about the effects that 
plaque accumulation or reduction might have on these cytokines.12 The use of cytokine 
measurements to assess the efficacy of oral hygiene aids will contribute to the understanding 
of the complex interaction of the bacterial challenge and the inflammatory and immune 
response of the patient.    
  
REVIEW OF THE LITERATURE 
A.  Cytokines 
 When a microbial challenge, as in plaque accumulation, is mounted against the host, a 
response is initiated which involves both saliva and the gingival crevicular fluid (GCF).  
Both of these have multiple capacities to deal with the bacterial challenge.  Within the GCF 
are a variety of cells including monocytes (macrophages) which serve as antigen-presenting 
cells.  These macrophages mediate the immune response when exposed to 
lipopolysaccharides by releasing chemical messengers called cytokines.13 Studies of early or 
experimental gingivitis show increases in inflammatory mediators (cytokines) in the gingiva 
and crevicular fluid.14,15   
 According to Seymour and Gemmell, “It is likely that the nature of the antigen-
presenting cell is fundamental in determining the nature of the cytokine profile, which may in 
turn open up possibilities for new therapeutic modalities.”11 These antigen-presenting cells 
plus peptides and proteins (cytokines) are part of the innate immune response which provides 
a rapid reaction to infections causing a pathological condition know as inflammation.16 
Cytokines are being studied to further the understanding of their role in the pathogenesis of a 
number of diseases because of their potential use as targets for therapy.17  
 Cytokines are low-molecular weight proteins involved in the initiation and effector 
stages of immunity and inflammation, in which they regulate the amplitude and duration of 
the response.  Cytokines are thought to selectively recruit and activate specific leukocytes to 
the sites of inflammation.13 According to Niederman et al, ‘tissue inflammation is associated 
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with increased levels of a variety of inflammatory mediators”.  They interact in a network; 
first by inducing each other, second by transmodulating cell surface receptors, and third by 
synergistic, additive, or antagonistic interactions on cell function.18    
  Among these cytokines are the chemokines MCP-1 and RANTES.  Chemokines are 
secondary pro-inflammatory mediators that recruit a well-defined subset of leukocytes; 
lymphocytes, monocytes, eosinophils, and basophils.  “Chemokines are induced by external 
signals such as IL-1 or TNF, growth factors, and viral and bacterial infection or their 
products.”19 MCP-1 and RANTES are in the CC group of chemokines that are chemotatic for 
monocytes and a small subset of lymphocytes.20 Emingil et al suggests that MCP-1 and 
RANTES could play a key role in both activation and recruitment of inflammatory and 
immune cells in the periodontal environment.21  
   Monocyte chemoattractant protein-1 (MCP-1) possesses a high degree of specificity 
for the recruitment and activation of monocytes to sites of injury and infection.  The 
accumulation of plaque on the teeth induces mononuclear phagocytes and endothelial cells to 
express MCP-1.20 In 1993, Yu et al, reported the first identification of expression of MCP-1 
or other members of the chemokine family in bacterially induced gingival inflammation.6 Yu 
et al also reported that MCP-1-producing cells are commonly found in inflamed gingiva.22 In 
1995 Graves reported that  
“The importance of MCP-1 in gingival inflammation is underscored by three recent 
findings: (1) the majority of mononuclear phagocytes in inflamed gingiva express 
MCP-1 (Yu and Graves, 1995); (2) MCP-1 expression is highly correlated with the 
degree of gingival inflammation present (Yu et al, 1993); and (3) MCP-1 is the 
principal monocyte chemoattractant in gingival crevicular fluid (Hanazawa et al, 
1993).”6,20,22,23   
 
 RANTES (regulated on activation, normal T cells expressed and secreted) activates 
monocytes, eosinophils and basophil leukocytes, inducing chemotaxis and release of other 
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cell mediators.24 RANTES acts as a chemoattractant for macrophages and lymphocytes.  
Gamonal and colleagues reported that higher levels of cytokines, including RANTES, were 
detected in the GCF of inflamed sites as compared to the healthy sites; however, their 
increase was not significant.  They stated that  
“These elevated GCF levels could not be correlated with any of the clinical 
parameters; probing depth (PD), clinical attachment loss (CAL) and the dichotomous 
measurements of supragingival plaque accumulation (PI), and bleeding on probing to 
the base of the crevice (BOP).  Their conclusions were that; 1). clinical parameters, 
such as PD, CAL, and BOP do not necessarily reflect current disease activity and 2). 
cytokine production does not necessarily reflect the presence of gingival 
inflammation but could be consistent with the divergence between clinical signs of 
inflammation and disease activity.”25   
 
 According to Embery and Waddington, “The collection of GCF is non-invasive, site-
specific about teeth, comparatively easy to perform, and offers one of the most accessible 
entrées of any tissue in the body as a means of assessing the disease state”.26  
B.  Dental plaque 
 The microbial etiological factor in periodontal diseases is dental plaque biofilm.  
Knowledge of the composition and structure of biofilm can help to explain why dental 
diseases occur and progress and, also, aid in effective therapeutic modalities.  Biofilm is an 
adherent mat of bacteria, epithelial cells, and leukocytes encased in a salivary glycoprotein 
and extracellular polysaccharide matrix that forms on inert surfaces.  Bacteria exhibit 
different properties when contained within a biofilm.  The biofilm associated with gingivitis 
is characterized by several cell layers (100-300), with bacterial stratification arranged by 
metabolism and aerotolerance.27 Marginal plaque, composed of filamentous microorganisms 
along with cocci and rods, is important in the initiation and development of gingivitis.    
 According to Dalwai et al, “plaque related diseases, such as gingivitis and 
periodontitis are linked to fluctuations in the oral environment which lead to a change in 
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microbial composition.”28 Changes in the microbial composition are related to an increase in 
plaque thickness.28 The strength of the inflammatory response appears to be related to the 
amount of plaque accumulation.29 Prolonged accumulation of dental plaque can induce the 
clinically observable signs of inflammation in the gingiva; edema, erythema and bleeding.30  
 In 1965, Löe and co-workers published their classic work that demonstrated that 
gingival health could be reliably achieved with immaculate oral hygiene and that gingival 
inflammation could be caused by the accumulation of plaque on the teeth.30 In fact, many 
oral diseases including dental caries, periodontal disease and peri-implantitis are plaque 
related.27  
C.  Periodontal Diseases 
 Periodontal disease, in its various forms, represents a nearly universal ailment.  
Approximately 50 % of the adults in the United States have gingivitis.1,31 Gingivitis, an 
inflammatory disease limited to the mucosal epithelium surrounding the cervical portion of 
the tooth and the alveolar processes, may be attributed to an accumulation of plaque biofilm 
in persons with inadequate oral hygiene.  It is initiated by bacterial colonization on the tooth 
surface.  If left untreated gingivitis can lead to the irreversible condition of periodontitis, an 
infection affecting the periodontal structures supporting the tooth; the attachment apparatus 
and bone.  Even though gingivitis does not always result in periodontitis, its effective 
treatment and prevention can improve oral health and reduce the incidence of periodontal 
diseases. 
 Periodontal disease presents a threat to the oral health of an individual and may 
contribute to the incidence and prevalence of systemic disease.  Systemic diseases such as 
cardiovascular disease,32,33 diabetes,34-36 rheumatoid arthritis,37,38 and adverse pregnancy 
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outcomes39-42 are being linked to periodontal disease as a possible risk factor. Recently Chen 
et al suggested that periodontitis may be associated with an increased risk of peripheral 
arterial disease.43   
 Periodontal disease can no longer be thought of as an ailment with relevance only to 
oral health.   The possible association between periodontal infection and systemic health has 
important implications for the treatment and management of patients.  As a result of the high  
cost of dental diseases and its impact on systemic health, some insurance companies are 
evaluating risk assessment as a tool to predict costs.44 Companies, such as Cigna, provide 
enhanced dental benefits for their subscribers during pregnancy45 to avoid  possible adverse 
pregnancy outcomes.  
D.  Toothbrushes 
 Bacterial plaque-induced gingivitis is the most common form of gingivitis.  The 
literature shows that gingivitis can be treated and controlled by thorough mechanical plaque 
removal and this is most often accomplished by using a toothbrush.  Manual toothbrushes, in 
their many designs, are most often used to help remove bacterial plaque and disrupt the 
inflammation that leads to gingivitis.46 No single manual design has demonstrated consistent 
superiority for either plaque removal or gingival inflammation reduction.46,47 The 
thoroughness and skill of the patient are the critical determinants and the ideal toothbrush 
design should be innovative enough to increase effectiveness in a manner independent of the 
patient’s skills or specific method of brushing.48   
 A variety of innovative powered toothbrushes have been introduced in an effort to 
improve upon the effectiveness of plaque biofilm removal.  Most of these rely on direct 
contact with the tooth surface.49 However; a manufacturer has introduced a sonic and 
  8 
ultrasonic brush that claims to remove plaque beyond where the bristles meet the teeth.   
Several in vitro studies have been conducted to test cleaning 3-4 mm beyond the reach of the 
bristles; however, they lack clinical support.50,51 If a powered brush enabled the user to 
remove plaque where the bristles do not touch the teeth (approximately 50% of the tooth 
surface) this would improve the oral health of the user.  Studies have shown that patient 
compliance with brushing is improved using powered toothbrushes52-54 
 This study investigated the effect of a powered toothbrush utilizing licensed 
technology developed at the University of Washington by Professor Pierre Mourad, 
incorporating both sonic and ultrasound physical processes.55 Sonic and ultrasound physical 
processes are a result of acoustical energy; the generation, propagation, and reception of 
mechanical waves and vibrations.  Sonic or audible vibrations occur within the range of 20 
Hz and 20,000 Hz and ultrasonic vibrations at frequencies greater than 20 KHz.  Sonic 
vibrations produce bubbles within a liquid environment.  These bubbles or cavitations are 
then activated by ultrasound transducers forcing them to oscillate, expand, contract and burst 
creating shear forces.  These shear forces break up and lift off contaminants on the surface 
being cleaned.  
   
   
  
MATERIALS AND METHODS 
 
 This study was a parallel study design with participants randomized to one of two 
treatment arms with the examiner(s) blinded to treatment.  The treatment group was assigned 
a powered toothbrush, and the control group a manual toothbrush. 
 Twenty participants were recruited from printed and electronic advertisements, and 
from the university’s recruitment database.  All participants had type I gingival disease56 with 
a minimum of 10 percent bleeding on probing scores and probing depths not to exceed 6 mm 
(excluding the distal surfaces of the most posterior teeth).   
 Participants were first appointed for a screening visit to obtain informed consent and 
determine eligibility for the study.  To be eligible for the study participants had to be in good 
overall health and between 18-65 years of age, have a minimum of 18 natural teeth, use floss 
less than 3 times a week, have a minimum BOP scores of 10% and be willing to use the study 
assigned products.  Potential participants were ineligible if they had an autoimmune disease, 
a cardiac pacemaker, used anti-inflammatory or immunosuppressant drugs or drugs that 
caused gingival enlargement, were pregnant or lactating, used tobacco products within the 
last six months prior to enrollment, were undergoing any extensive dental or orthodontic 
treatment, had a professional prophylaxis within 1 month, were currently using bleaching 
trays, had used a powered toothbrush in the last two months or had any condition that 
required antibiotic prophylaxis prior to periodontal probing or periodontal therapy.  Once 
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eligibility was determined participants were appointed for four additional visits over the next 
six months.  
 A medical history was collected at the screening visit and reviewed at each 
subsequent visit.  An intraoral exam was conducted at each visit and any adverse events were 
reported according to the University guidelines.  For study visits 2-4 participants were 
instructed to not eat within one hour of the study visit and to discontinue brushing or using 
any other oral hygiene aids 18-24 hours prior to the appointment.  Participants were to use 
the test brush (either the powered or manual brush) at home (2 times per day per written 
instructions) with the study toothpaste.  (Appendix 1)  Participants were instructed not to use 
any products other than those assigned in the study including; mouth rinses, chewing gum, or 
whitening products.  
 During the study visits participants received a complete oral examination including 
plaque index, gingival index, probing depths, clinical attachment level, and bleeding upon 
probing.  Gingival crevicular fluid samples were collected for analysis to determine the 
concentration of MCP-1 and RANTES. (Appendix 2) The following is a list of all procedures 
that were conducted during each appointment. 
    
Six weeks Six weeks Twelve weeks 
Visit 1 
Screening 
Visit 2 
Baseline 
Visit 3 Visit 4 Visit 5 
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Visit 1: Screening 
• Study consent form signed 
• Medical history completed and reviewed 
• Inclusion and exclusion criteria reviewed 
• Intra oral exam 
• Gingival index (full mouth) Sites >2 recorded on CRF 
• Plaque and stain index recorded 
• Periodontal probing depth measurements recorded (full mouth) 
• Clinical Attachment levels measured and recorded  
• Bleeding on  probing (BOP) recorded 
• GCF and plaque sampling sites identified and recorded on CRF 
• Participant compensated for screening visit 
Visit 2: Baseline 
• Medical history reviewed  
• Intra oral exam  
• Baseline gingival crevicular fluid samples (GCF) will be taken from previously 
identified sites  
 
• Plaque and stain index recorded  
• Gingival index (full mouth)  
• Probing depth and clinical attachment level data transferred from screening visit 
data 
 
• Baseline plaque samples taken from previously identified sites 
• Study toothbrush and toothpaste dispensed via randomization schedule 
• Product training (according to written brushing instructions) (Appendix 1) 
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• Participant brushes with study brush and toothpaste (supervised by a dental 
professional) 
 
• Adverse events documented on CRF 
• Compliance telephone calls will be placed to all participants 3 weeks after 
 visit 2 
 
Visit 3-5:  
• Medical history reviewed and compliance verified  
• Intra oral exam 
• GCF samples taken from pre-identified test sites (same as baseline) 
• Plaque and stain index recorded 
• Gingival index (full mouth) 
• Probing depth measured and recorded (full mouth) 
• Clinical Attachment levels measured and recorded 
• BOP recorded 
• Adverse Events documented on CRF 
• Product use reinforced and usage instructions reviewed (2 minutes twice per day 
home use) (Appendix 1) 
 
• Powered toothbrush handle checked to ensure working properly 
• Powered brush head replaced or manual toothbrush replaced and additional 
toothpaste dispensed if needed 
 
• Used brush heads collected 
• Participants assigned to powered toothbrush completed questionnaire 
• Compliance telephone calls were placed to all participants 3 weeks after visit.  
 Prior to Visit 1, the examiner(s) were be calibrated for accuracy and repeatability 
using the Silness and Löe Plaque and Stain Index, Löe and Silness Gingival Index, 
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periodontal pocket depth and clinical attachment levels using the UNC-15 periodontal probe. 
The purpose of this examiner calibration session was to quantify intra- and inter-examiner 
reliability of measuring periodontal soft and hard tissue parameters. All examiners 
participated, and examiner calibration was conducted at the University of North Carolina 
School of Dentistry in the GO Health Center.  The Kappa statistic for inter-examiner 
reliability showed almost perfect agreement for probing depth measurements and full 
agreement for clinical attachment level measurements (r = 0.91 and r = 0.80, respectively).57  
Data Analysis 
 Descriptive statistics and statistical analyses were performed with the computerized  
statistical packages (JMP and SAS). 
 Participants were randomly assigned to treatment using a randomization schedule 
created by the study statistician. All biological samples and data were coded and all personal 
information was removed and would not be linked to the data. 
 Initial descriptive analyses summarized subject-level mean scores within treatment 
groups at baseline, and in particular, any imbalances between the randomized groups at 
baseline were identified.  The baseline characteristics of race, gender and frequency of dental 
visits were analyzed using a chi-square model.  Age was analyzed using an unpaired t-test 
model.  Two-sample t-tests for the comparison of mean levels of the treatment and control 
groups were conducted at each visit for the clinical measurements and the MCP-1 and 
RANTES concentrations.  All MCP-1 and RANTES levels were reported in log base 10.  
The analysis of covariance (ANCOVA) model was used to compare the clinical 
measurements and GCF levels at 24 weeks post therapy with baseline, adjusting for baseline 
levels. 
  
RESULTS 
Patient Population 
  A total of 20 participants (11 males and 9 females) completed the 24 week clinical 
phase of this study.  Of the 20 participants enrolled, 10 (50%) were randomly assigned to the 
powered toothbrush group and 10 (50%) to the manual toothbrush.  The baseline data was 
recorded for all 20 participants; however, due to technical problems, the data used at 24 
weeks post treatment to compute the analysis of covariance (ANCOVA) for the clinical 
measurements was recorded on 18 participants and the data for the GCF levels was recorded 
on 19 participants. (Figure 1)   
 No adverse events were reported during the study.  There were five protocol 
deviations recorded for the treatment group and seven for the control group which included 
doctor visits, dental visits with restorative treatment and insertion of orthodontic spacers, 
medication changes, out of window study visits and inability to use study brush while on 
vacation.    
 Table 1 shows, for each of the two groups (treatment and control), the baseline results 
for four key variables; gender, race, age, and frequency of dental visits. The non-significant, 
chi-square test results for baseline gender and frequency of dental visits; and the non-
significant unpaired t-test results for age, indicate that the two groups were well balanced at 
the start of this clinical trial with the exception of the racial demographic.  It can be observed 
that only race shows a statistically significant difference between the treatment group and the 
control group (chi-square p=0.01). 
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Clinical Measurements 
 The baseline analysis of the dental index scores between the two groups (treatment 
and control) appears in Table 2.  An unpaired t-test was used to determine significance 
between the mean dental index scores for the treatment group and the control group.  There 
were no statistically significant differences for the clinical measurements (probing depth 
(PD), extent PD≥4mm., gingival index (GI), extent GI≥2mm, plaque index (PI), clinical 
attachment loss (CAL), extent CAL≥3mm, bleeding on probing (BOP), again indicating a 
balanced group at the start of the clinical trial.   
 Using the analysis of covariance (ANCOVA) model, Tables 3 shows that the dental 
index scores for PD, extent PD, GI, extent GI, PI, CAL, extent CAL, and BOP for the 
treatment group and the control group were not statistically different, at baseline and 24 week 
post treatment, adjusting for baseline levels.  
MCP-1 and RANTES  
 Table 2 shows the non-significant, unpaired t-test results for baseline gingival 
crevicular fluid (GCF) levels of MCP-1 and RANTES.  These results indicate that the two 
groups were well balanced at baseline when comparing these mediator levels.   
 The analysis of covariance (ANCOVA) model was used to determine if there were 
differences between the mean GCF levels of MCP-1 for both groups (treatment and control) 
at baseline and at 24 week post therapy, adjusting for baseline levels,.  Although GCF MCP-
1 levels were lower at 24 weeks post therapy in the treatment group, the reduction was not 
statistically significant. (Table 3). 
 Table 3 also shows the comparison of the GCF levels of RANTES for the treatment 
group and the control group at baseline and 24 week post therapy, adjusting for baseline 
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levels.  Although the GCF levels of RANTES were lower at 24 weeks post therapy for both 
the treatment and control group, these results were not statistically significant using the 
analysis of covariance (ANCOVA) model. 
 Mean GCF MCP-1 and RANTES levels for the treatment and control groups were 
compared at each visit and analyzed using a two-sample t-test.  There were no statistically 
significant differences between the groups at any of the visits.  However, trends in the 
reduction of these mediators are shown in figure 2 for MCP-1 mean levels and figure 3 for 
RANTES mean levels by visit.
  
DISCUSSION 
 Powered toothbrushes are being developed that utilize advancements in technology to 
offer the consumer products that have the potential to achieve better plaque removal in a 
more efficient manner.  Recently, a powered toothbrush that incorporates both sonic and 
ultrasound physical processes was introduced.  This pilot study attempted to assess the effect 
a powered toothbrush that utilizes this innovative technology would have on indicators of the 
inflammatory response, the cytokines MCP-1 and RANTES.  
 Most studies utilize dental indices, probing depths, clinical attachment level and 
bleeding on probing to quantify the amount and severity of disease and to follow any changes 
in gingival status over specified periods of time.  The use of these clinical measurements 
does not necessarily reflect gingival health or the risk of disease progression.  Bleeding on 
probing provides a much better indicator of inflammation and disease progression but is not 
the most sensitive or specific measure of health.   
 The addition of analyzing cytokine levels to evaluate the effect of a powered 
toothbrush will add insight into the complex interaction of the biofilm with the host 
inflammatory and immune response.  The increased concentration of cytokines in the 
gingival crevicular fluid of inflamed gingival tissue might precede the clinical signs of 
inflammation and provide earlier therapeutic intervention to prevent the progression of 
disease. The analysis of cytokine levels also provides a quantitative measure of the success of 
therapy as well as providing a profile of each patient’s unique inflammatory response.  
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Treatment modalities which focus on the host reaction as well as the bacterial challenge offer 
the clinician a different therapeutic approach to treating disease.  
 The lack of significant findings in this pilot study could be attributed to the fact that 
the study did not have sufficient power to detect significant differences.  In future studies 
having a larger patient sample size to assess GCF levels of MCP-1 and RANTES could 
possibly increase the significance of MCP-1 and RANTES.  Even though a trend in the 
reduction in the biochemical mediators in patients using the powered toothbrush when 
compared to a manual toothbrush was observed, this reduction was not significant.  The 
results of this study do not support the ability of either the powered toothbrush or the control 
brush to reduce the concentration of the inflammatory mediators MCP-1 and RANTES over 
a 6 month period.   
 The selection of the mediators, MCP-1 and RANTES, might also account for their 
non-significant reduction in response to therapy.  MCP-1 and RANTES levels are directly 
related to the degree of inflammation and their expression is induced by other cytokines and 
cell components.  It could be that gingivitis patients in this study did not have the level of 
disease that would illustrate a reduction in the concentration of these chemoattractant 
cytokines.  Further studies in populations with gingivitis using different mediators are needed 
to evaluate this finding. 
 The collection of GCF, while non-invasive, is technique sensitive.  It is possible that 
the samples collected in this study were contaminated with plaque, blood or saliva.  
 This pilot study will contribute to the body of knowledge within the National Dental 
Hygiene Research Agenda by validating and testing mechanisms that increase health 
promotion and disease prevention among a diverse population.58 This pilot study tested the 
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efficacy of a powered toothbrush by utilizing cytokine measurements as indicators of a 
reduction in the inflammatory response.  Cytokines offer an additional method of validating 
the efficacy of oral hygiene aids.  
 This pilot study was nested within a larger, ongoing study of 84 participants.  The 
overall study is investigating the cytokine levels of Il-1β, Il-6 and Il-8, analyzing the 
microbial composition of the plaque and comparing the clinical measurements between the 
powered toothbrush group and the manual toothbrush group. 
 
  
CONCLUSION 
  
 Innovative powered toothbrushes are being introduced to provide the consumer with 
products that more effectively remove plaque biofilm and consequently, improve oral health.  
Even though this study did not show that a powered toothbrush, combining sonic and 
ultrasound technology, was more effective than a manual brush in reducing the levels of 
cytokines, further studies are needed to examine and evaluate this novel technology.   
 To test the efficacy of therapeutic devices such as toothbrushes, investigators utilize 
measurements of clinical parameters.  No other studies have been located in the literature that 
address the use of cytokines to assess the effect of a powered toothbrush. The addition of 
analyzing cytokine levels will offer insight into the interaction of the biofilm with the host 
inflammatory and immune response.   
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TABLE 1 
 
Baseline Subject Characteristics by Group 
 
 
 
 †Statistically significant p<0.05 
1Treatment group:  Subjects using the powered toothbrush 
2Control group:  Subjects using the manual toothbrush 
 
 
 
 
 
 
 
 
 
 
 
Subject Characteristic  Treatment 
Group1 
 
Control 
Group2 
 
P value 
Subjects (n {% total})  10 (50%) 10 (50%)  
Male 6 (30%) 5 (25%) Gender  
Female 4 (20%) 5 (25%) 
0.65 
African 
American 
1 (5%) 6 (30%) 
Caucasian 9 (45%) 4 (20%) 
Asian   
Native 
American/ 
Alaska Native 
  
Race 
Other    
0.01† 
6 months 8 (40%) 5 (25%) 
12 months 1 (5%) 5 (25%) 
Frequency of dental 
visits 
Infrequent/ 
over 12 months 
1 (5%) 0 (0%) 
0.08 
Age (years;mean {SD})  40.8 (12.59) 38.6 (11.34) 0.68 
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TABLE 2 
 
Baseline Periodontal Clinical Measurements and GCF MCP-1 and 
 RANTES Levels by Group 
 
 
 
 
1Treatment group:  Subjects using the powered toothbrush 
2Control group:  Subjects using the manual toothbrush   
 
 
 
 
 
 
 
 
 
 Treatment Group1 
Mean/SD 
Control Group2 
Mean/SD 
P value 
Clinical Measurements    
PD  2.03 (0.33) 2.18 (0.55) 0.49 
Extent PD≥4mm  6.16 (5.56) 8.62 (7.02) 0.40 
GI  0.97 (0.45) 1.28(0.22) 0.06 
Extent GI ≥2  27.09 (26.37) 41.44 (19.65) 0.18 
PI  0.47 (0.27) 0.79 (0.44) 0.07 
CAL  1.65 (0.39) 1.58 (0.38) 0.67 
Extent CAL≥3mm 13.03 (8.27) 11.50 (9.09) 0.70 
BOP 47.10 (16.49) 60.33 (16.91) 0.09 
GCF Levels (log)    
MCP-1 0.33 (0.29) 0.36 (0.26) 0.79 
RANTES 0.17 (0.31) 0.36 (0.61) 0.40 
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TABLE 3 
 
Baseline and 24 Weeks Post Therapy for Outcome Variables by Group 
 
 
 
1Treatment Group:  Subjects using the powered toothbrush 
2Control Group:  Subjects using the manual toothbrush
 Treatment Group¹ 
Mean/SD 
 
Control Group² 
Mean/SD 
P 
value 
 Baseline 24 Weeks 
Post Therapy 
Baseline 24 Weeks  
Post Therapy 
 
Clinical 
Measurements 
     
PD 2.04 (0.33) 1.84 (0.28) 2.18 (0.55) 1.97 (0.33) 0.33 
Extent 
PD≥4mm 
 
6.16 (5.56) 
 
3.14 (4.66) 
 
8.62 (7.02) 
 
6.01 (6.94) 
 
0.45 
GI 0.97 (0.45) 1.11 (0.37) 1.29 (0.21) 1.24 (0.30) 0.44 
Extent 
GI≥2mm 
27.09 (26.37) 37.78 (25.14) 41.12 (18.68) 38.15 (29.02)  
0.93 
PI 0.47 (0.27) 0.86 (0.51) 0.81 (0.42) 1.13 (0.42) 0.59 
CAL 1.65 (0.39) 1.29 (0.32) 1.58 (0.38) 1.10 (0.20) 0.24 
Extent 
CAL≥3mm 
 
13.03 (8.27) 
 
4.59 (5.70) 
 
11.50 (9.09) 
 
4.40 (4.45) 
 
0.87 
BOP 47.10 (16.49) 43.72 (17.90) 60.33 (16.91) 51.96 (23.11)  
0.64 
GCF Levels 
(log) 
     
MCP-1 0.33 (0.29) 0.15 (0.20) 0.36 (0.26) 0.36 (0.43) 0.20 
RANTES 0.17 (0.31) 0.11 (0.23) 0.36 (0.61) 0.30 (0.41) 0.19 
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FIGURE 1 
 
Flow Diagram 
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FIGURE 2 
 
Descriptive Statistics for MCP-1 for the Treatment Group Illustrating the  
Trend over Time 
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FIGURE 3 
 
Descriptive Statistics for RANTES for the Treatment Group Illustrating the  
Trend over Time 
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Appendix 1 
 
Powered Brushing Instructions 
 
The Ultreo has a 2-minute brushing feature which automatically turns off after 2 minutes.  
Follow these simple steps to maximize your brushing experience:  
 
 
1. Place a small amount (approximately pea-sized) of toothpaste on the 
center of the brush head and wet the brush under running water.  Before 
turning the Prototype on, place the bristles of the brush head in the back 
section of your mouth pointing toward the gum line.   
 
2. Hold the handle with a light ‘finger-tip’ grip and turn on the powered 
toothbrush.  
 
3. Gently move the brush in a slightly circular motion so the bristles penetrate between your 
teeth and into your gum line.  After a few seconds, continue brushing to the next section 
while you gently circulate the bristles. Do not scrub.  Continue brushing 
throughout your mouth evenly to effectively remove plaque in those hard-
to-reach places.   
 
4. The angled brush head and slender neck help you reach the back teeth 
and the tooth surfaces on the inside of the mouth. Be sure to adjust your 
brushing to use the angle to your advantage and keep as many bristles in 
contact with the teeth as possible.  
 
5. To make sure you brush evenly throughout the mouth, divide your mouth into 4 sections: 
1) outside lower teeth, 2) inside lower teeth, 3) outside upper teeth and 4) inside upper teeth. 
Begin brushing in section 1 (outside lower teeth) and brush for 30 seconds before moving to 
section 2 (inside lower teeth).  Continue similarly to upper teeth.  You will hear a tone after 
30 seconds signaling you to move on to each section until you’ve brushed for 2 minutes.   
 
6.  In order to take fully advantage of the ultrasonic feature, keep as much fluid in your 
mouth as comfortable during brushing. 
 
Participant Reminders: 
1. Brush two minutes twice per day with the study toothbrush and toothpaste. 
2. Do not use other oral hygiene aids during the test period. 
3. Do not brush or use dental floss 18 – 24 hours prior to your next study visit. 
4. Do not eat 1 hour prior to your next study visit. 
 
3 
4 
1 2 
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Manual Brushing Instructions 
 
• Place your toothbrush at a 45-degree angle against the gums. 
• Move the brush back and forth gently in short (tooth-wide) 
strokes.  
• Brush the outer tooth surfaces, the inner tooth surfaces, and the 
chewing surfaces of the teeth.  
• Use the "toe" of the brush to clean the inside surfaces of the front 
teeth, using a gentle up-and-down stroke.  
• Brush your tongue to remove bacteria and freshen your breath.  
 
Participant Reminders: 
1. Brush two per day with the study toothbrush and toothpaste. 
2. Do not use other oral hygiene aids during the test period. 
3. Do not brush or use dental floss 18 – 24 hours prior to your next study visit. 
4. Do not eat 1 hour prior to your next study visit. 
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Appendix 2 
Clinical Measurements    
 
 Full Mouth Probing Depths – A manual UNC -15 periodontal probe will be used to 
measure probing depths at 6 sites per tooth, on all teeth present in the mouth except 
third molars and the distal surfaces the second molars.  The distance between the 
gingival margin and the apical depth of the probe tip penetration will be measured.  
When interproximal measurements are taken, the probe will be placed with a slight 
angulation from the buccal toward the lingual, or visa versa, touching the contact 
area, but still keeping the shaft of the probe as parallel to the long axis of the root as 
possible.  A probing force of between 20 to approximately 30 grams, which is 
described in the periodontal literature as “light hand pressure,” will be used.  All 
measurements will be rounded up to the nearest millimeter. 
   
 Clinical Attachment Levels (CAL): A manual periodontal probe will be used to record 
recession at 6 sites per tooth, excluding 3rd molars.  Recession will be measured from 
the cemento enamel junction (CEJ), to the free gingival margin.  If the free gingival 
margin is below the CEJ recession will be measured and recorded on the appropriate 
CRF.  
 
 Bleeding on Probing (BOP):  BOP will be assessed and recorded after probing 
 measurements and CAL are taken for each quadrant. BOP will be recorded for six 
 sites for all teeth present in the mouth.  
 
 Silness and Löe Plaque and Stain Index- Plaque and stain indices will be scored for 
three facial surfaces (distofacial, facial, mesiofacial) and the direct lingual surfaces of 
each tooth using the Silness and Löe index.  The scores are determined based on a 0 - 3 
scale.  The tooth surface to be scored should be air dried and not disclosed.  The plaque 
and stain index is recorded in the appropriate boxes for each tooth on the computer 
screen. 
0 = absence of plaque or stain of the clinical crown                
1 = deposits covering less than one-third of the surface   
2 = deposits covering less than 2/3 of the surface 
      3 = deposits covering more than 2/3 of the surface 
 
 Löe and Silness Gingival Index - The degree of inflammation and/or bleeding of the 
gingival tissues will be evaluated using the Löe and Silness Gingival Index to evaluate 
improvement in gingival health over time.  The Löe and Silness Gingival Index assesses 
gingival health (inflammation and bleeding) on a scale of 0 to 3, with 0 = no 
inflammation or bleeding, 1 = inflamed appearance but no bleeding upon probing, 2 = 
appears inflamed and bleeds when pressure applied on the gingival with a periodontal 
probe, and 3 = spontaneous bleeding upon application of pressure with the periodontal 
probe.  Gingivitis is assessed at 4 sites per tooth (distal, buccal, mesial and lingual). 
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 Gingival Crevicular Fluid:  Gingival Crevicular Fluid (GCF) samples will be 
collected from the two deepest pocket depths in each quadrant.  If there are identical 
measurements in a quadrant then the most posterior sites will be chosen for collection.  
Prior to collection the dental examiner and research assistant will be gloved and care will 
be taken to maintain the sterility of the periopaper (Perio-strips Ora Flow Inc, Plainview 
NY) used to collect GCF samples. 
  
 Prior to collection, the site will be dried and isolated with a cotton roll.  After 
isolating the site, a periopaper strip will be inserted into the sulcus and gingival crevicular 
fluid will be absorbed on the filter end of the strip.  Once the periopaper has absorbed the 
GCF it will be read using a periotron.  Acceptable readings will measure between 30 -
180.  If a strip reads outside of these measurements an additional strip will be placed and 
read until an acceptable reading is obtained. Once an acceptable reading is collected, the 
measurement will be entered into the database and the strip will be removed from the 
periotron and immediately rolled into aluminum foil, taking care to avoid touching the 
filter end of the strip.  This will continue until one strip from each quadrant is collected 
and rolled in the aluminum foil.  Once four strips are collected and rolled together the foil 
will be placed in a bar-coded cryovial and dropped into liquid nitrogen chair side for snap 
freezing.   
 
 Plaque Samples: Plaque samples will be collected at the completion of the 
periodontal examination from the deepest subgingival area in each quadrant with a sterile 
periodontal curette.  Each sample taken will be placed in a pre-labeled  vial containing 
150 µl of TE buffer. Once each sample is collected, 150 µl of freshly made 0.5 M NaOH 
will be added and the sample will be vortexed. 
 
 Sites designated for sampling are identified to the Examiner in a report from the 
Dental Data Entry System (DDES), and run at the completion of the examination entry.   
Sites must be sampled in quadrant order and tube order, such that the sample from each 
quadrant is placed in the tube with the corresponding bar-coded label.  Sterile TE (Tris-
EDTA) buffer will be available and remains stable at room temperature.  Using a Repipet 
device add 150µL of TE buffer to each of these vials prior to plaque sampling.  TE 
should be added between 0-72 hours prior to plaque sampling. Using care to make sure 
the plaque sample from each quadrant goes into vial with the corresponding bar-coded 
label, place the tip of the curette into the TE and twirl the curette so that the plaque is 
visibly transferred into the buffer for each of the tubes.  If a particularly heavy deposit 
adheres to the curette, it may be removed by scraping the tip of the curette onto the upper 
lip of the tube, and then pushing the sample down into the buffer.  
  
 However, in general, sufficient bacteria will be transferred to the buffer for DNA 
analysis, even if not visible by eye.  Then, using a different Repipet device, clearly 
labeled for NaOH (Sodium Hydroxide) add 150 µL of the NaOH to each collection vial, 
cap tightly, and vortex to achieve good mixing of the buffer and the NaOH.  Personnel 
should use caution whenever working with the NaOH as this is a strong base and can 
cause burns on skin and clothing.  This procedure is repeated for the remaining 3 
quadrants.  Samples for each quadrant are placed in separate appropriately labeled vials. 
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